Evolus (FRA:EVL) Other Long-Term Liabilities : €30.6 Mil (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Evolus Other Long-Term Liabilities?

Evolus's other long-term liabilities for the quarter that ended in Mar. 2025 was €30.6 Mil.

Evolus's quarterly other long-term liabilities increased from Sep. 2024 (€31.2 Mil) to Dec. 2024 (€32.0 Mil) but then declined from Dec. 2024 (€32.0 Mil) to Mar. 2025 (€30.6 Mil).

Evolus's annual other long-term liabilities declined from Dec. 2022 (€37.6 Mil) to Dec. 2023 (€33.2 Mil) and declined from Dec. 2023 (€33.2 Mil) to Dec. 2024 (€32.0 Mil).

Evolus Other Long-Term Liabilities Historical Data

The historical data trend for Evolus's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolus Other Long-Term Liabilities Chart

Evolus Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Long-Term Liabilities

Get a 7-Day Free Trial

47.76

39.32

37.62

33.20

32.04

Evolus Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Long-Term Liabilities	Get a 7-Day Free Trial															32.57	32.14	31.18	32.04	30.60

Evolus Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Evolus Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Evolus's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Evolus Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evolus Inc (FRA:EVL) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

EOLS:USA EVL:Germany

Address

520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660

Website

https://www.evolus.com

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Evolus Headlines

No Headlines